Ovarian cancer detection
This article was originally published in The Gray Sheet
Executive Summary
Protein patterns in blood samples are able to detect 100% of Stage I ovarian cancer cases, according to a "fast-track" study published on The Lancet website Feb. 8. Conducted by the National Cancer Institute, FDA and Correlogic Systems, the Bethesda, Maryland-based developer of the Proteome Quest test, the study analyzed 116 blinded blood samples - 50 with cancer and 66 with non-malignant disease. The bioinformatic test correctly identified all 50 cases of ovarian cancer and 63 (95%) control cases. Correlogic is involved in a two-year cooperative research and development agreements with FDA/NCI Clinical Proteomic Program; additional trials are underway at NCI to confirm specificity and sensitivity of the test and access its efficacy as a stand-alone device...